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ABSTRACT
Introduction: : Emerging studies suggest that antibiotic pharmacokinetics (PK) are difficult to predict in 
critically ill patients. The high intra- and inter-patient PK variability makes it challenging to accurately 
predict the appropriate dosage required for a given patient. Identifying patients at risk could help 
clinicians to consider more individualized dosing regimens and perform therapeutic drug monitoring. 
We provide an overview of relevant predictors associated with target (non-)attainment of β-lactam 
antibiotics in critically ill patients.
Areas covered: : This narrative review summarizes patient and clinical characteristics that can help to 
predict the attainment of target serum concentrations and to provide guidance on antimicrobial dose 
optimization. Literature was searched using Embase and Medline database, focusing on β-lactam 
antibiotics in critically ill patients.
Expert opinion: : Adequate concentration attainment can be anticipated in critically ill patients prior to 
initiating empiric β-lactam antibiotic therapy based on readily available demographic and clinical 
factors. Male gender, younger age, and augmented renal clearance were the most significant predictors 
for target non-attainment and should be considered in further investigations to develop dosing 
algorithms for optimal β-lactam therapy.
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1. Introduction
Severe bacterial infections are a major challenge in the inten-
sive care unit (ICU) because of their high prevalence and 
mortality. Early adequate antimicrobial therapy improves the 
likelihood of clinical cure and survival rates [1–3]. However, 
dosage guidelines for most antibiotics are derived from phar-
macokinetic (PK) studies in healthy volunteers, and do not 
consider the significant changes in PK and pathogen suscept-
ibility that are common to the critically ill patient. For example, 
changes in drug clearance and/or volume of distribution can 
lead to significant changes in the plasma drug concentration 
[4,5], resulting in predetermined pharmacokinetic/pharmaco-
dynamic (PK/PD) targets not being achieved and thus a higher 
treatment failure rate [6]. Furthermore, critically ill patients can 
undergo rapid physiological changes, such as altered fluid 
status, changes in serum albumin concentrations, end-organ 
dysfunction, systemic inflammatory response syndrome (SIRS), 
and microvascular failure [4,7]. These factors imply that anti-
biotic dosing in critically ill patients demands a thorough 
assessment and the need for an individualization from initia-
tion of the therapy and during the course of treatment [8,9].
β-lactam antibiotics (penicillins, cephalosporins, monobac-
tams, and carbapenems) are amongst the most commonly 
used antibiotics to treat severe infections in the ICU because 
of their broad spectrum, low likelihood of drug-drug interac-
tions, and wide therapeutic range. These antibiotics display 
a time-dependent activity. The pharmacodynamic index asso-
ciated best with a high probability of successful outcome is 
the percentage of time (T) of the dosing interval in which the 
unbound (free, ƒ) serum antibiotic concentration remains 
above the minimum inhibitory concentration (% ƒT > MIC). 
For β-lactams, the ƒT > MIC value needed for bactericidal 
activity is between 40% and 70% in in vitro infection models 
[10,11], this has been confirmed in patients with nosocomial 
pneumonia for both ceftazidime and ceftobiprole [12,13]. 
However, clinical data suggest optimal efficacy is achieved at 
100% ƒT > MIC in critically ill patients [14–17].
Achieving the high ICU targets is not easy, particularly 
when fixed conventional β-lactam dosing regimens are 
used. Although β-lactam antibiotics have a relatively wide 
therapeutic window, simply increasing the standard dosing 
for this group of antibiotics in all critically ill patients is not 
an optimal strategy, since high dosing regimens might 
result in trough levels associated with overexposure and 
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toxicity [18]. Looking at the current standard approach, 
dose adjustment and optimization is made only based on 
indication and adjusted for renal function. Moreover, 
appropriate antimicrobial therapy refers not only to 
a suitable drug choice in terms of spectrum of activity, 
but also to an adequate dosing regimen. Thus, it appears 
necessary to individualize β-lactam dosing regimens in 
critically ill patients. Accordingly, identifying patients at 
risk could guide clinicians to consider more individualized 
dosing regimens and incorporate therapeutic drug moni-
toring (TDM) when needed.
The purpose of this review is to examine recent evi-
dence on relevant demographic and clinical characteristics 
predicting β-lactam exposure in critically ill patients and to 
provide dosing recommendations.
2. Methodology
A literature search was conducted in August 2020 without 
a restriction of the publication date. Two databases (Medline 
All Ovid and Embase) were searched to assess literature on risk 
factors to predict target concentration prior to initiating 
empiric β-lactam therapy in critically ill patients. The search 
was additionally limited to English-language articles. Detailed 
research terms can be found in supplementary Table S1.
2.1. Eligibility criteria and study selection
Studies reporting the relationship between patient or clinical 
variables and target (non-)attainment at the time of β-lactam 
antibiotics treatment initiation in critically ill patients were 
eligible for inclusion. Titles and abstracts were screened to 
identify relevant publications. Articles were excluded if they 
assessed pediatric patients, or were clinical cases, reviews, 
letters or editorials. Reference lists of eligible studies were 
searched for additional studies. The references from the data-
base were imported into a reference manager (Endnote X9®).
2.2. Data extraction
We extracted the following data from each included study: 
author, year of publication, study antibiotics, number of par-
ticipants, and the effect of the predictor on β-lactam target 
attainment. The estimates for the multivariate regressions 
examining the association of target attainment with predic-
tor variables were extracted. For the effect size we have 
reported the odds ratios (ORs) and the 95% confidence inter-
vals (95% CI). In studies in which the relationship with target 
non-attainment was investigated, the OR was converted to 
the inversed OR (1/OR).
3. Predictors for β-lactam exposure
3.1. Study selection
Figure 1 shows a flowchart of the selection process by which 
articles were identified. Using the search process described 
above, 839 studies remained once duplicates were removed. 
A total of 20 studies were included for the full-text assessment. 
Of these, 11 studies were found that met the inclusion criteria, 
representing 11 different β-lactam antibiotics (3 penicillins, 6 
cephalosporins, and 3 carbapems) [16,19–28]. Only four stu-
dies were primarily designed to assess the relationship 
between drug concentrations or target attainment and risk 
factors [19,21,24,27]. Almost all studies were partly or fully 
performed in European hospitals (n = 10, 91%). Taken 
together, results suggest that β-lactam exposure is associated 
with a wide range of demographic and clinical characteristics 
(Figure 2). Details on the factors that predicted the achieve-
ment of the PK/PD targets (Cmin> MIC, 50% (ƒ)T > MIC, 100% 
(ƒ)T > MIC, and 100% (ƒ)T > 4× MIC are shown Table 1.
3.2. Demographic predictors
We found two demographic characteristics that can be 
used at the start of empirical antibiotic therapy to poten-
tially increase the chance of target attainment. Firstly, male 
gender is significantly associated with target non- 
attainment [19,20,27]. On average, men have a larger 
volume of distribution (plasma volume and intra-/extracel-
lular water) and a higher drug clearance, possibly explain-
ing the observed effect of gender on drug exposure [29]. 
Furthermore, male gender is thought to offer an under-
lying physiological reserve to critically ill patients and con-
tribute to target non-attainment by facilitating augmented 
renal clearance (ARC) [30]. Although gender is easy to 
implement in predictor models for target attainment, 
future studies should be designed with a primary focus 
on this topic to better understand the basic mechanisms 
of gender differences and the implications for clinical 
management.
Age is the second demographic predictor that was found to 
be significantly correlated with target attainment [20,27]. This 
association is related to the presence of reduced renal func-
tion, which is common in older patients.
3.3. Clinical predictors
We found various clinical characteristics that can be used 
at the start and during empirical antibiotic therapy to 
optimize target attainment. Evidence suggests that renal 
function is among the most important clinical factor to 
contribute to target non-attainment at the time of anti-
biotic initiation [16,19–25,27,28].
Article highlights
● This review provides an overview of important predictors for β-lactam 
target (non)-attainment in critically ill patients.
● Adequate target attainment can be anticipated in critically ill patients 
prior to initiating empiric β-lactam antibiotic therapy based on readily 
available demographic and clinical factors.
● Male gender, younger age, and augmented renal clearance are the 
most significant predictors for β-lactam target non-attainment.
● A higher daily dose of β-lactam antibiotics at the onset of treatment 
should be considered in the most critically ill patients and in those with 
preserved renal function or augmented renal clearance.
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Traditionally, renal function in critically ill patients has been 
routinely assessed with the objective of detecting renal 
impairment and adjusting drug doses. Nevertheless, ARC has 
also been identified in ICU patients [30,31]. As a result, 
patients with presumed ‘normal’ or increased renal function 
are at risk of target non-attainment [32]. The PK of critically ill 
patients can be significantly altered due to an increased car-
diac output with resultant of increased renal blood flow and 
this may lead to ARC of solutes and drugs [33,34]. 
Furthermore, as β-lactam antibiotics are hydrophilic com-
pounds and are predominantly cleared by the kidney, high 
renal function, as observed in ARC, contributes significantly to 
suboptimal target attainment [16]. Although there is no final 
consensus as to what defines ARC of drugs, a recent definition 
suggests ARC when the creatinine clearance (CLCr) exceeds 
130 mL/min per 1.73 m2 [35]. Udy et al. examined the CLCr 
and β-lactam trough concentrations of 58 intensive care unit 
(ICU) patients, CLCr values ≥130 mL/min/1.73 m2 were 
Figure 1. Flowchart of the search strategy and included articles.
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associated with trough concentrations less than the MIC of the 
antibiotic needed to inhibit the targeted micro-organism in 
82% of patients [32]. Imani et al. assessed the performance of 
eGFR as an independent predictor for target non-attainment 
using a ROC curve and found an eGFR threshold value of 
≥71.5 mL/min/1.73 m2 had a sensitivity and specificity of 
77% and 65%, respectively [27]. Furthermore, Carrié et al. 
reported that eGFR ≥170 mL/min were significantly associated 
with ƒT < 4× MIC [23]. The ability to rapidly predict the risk of 
target non-attainment in patients with ARC using available 
eGFR has considerable clinical value. Moreover, the emer-
gence of ARC itself has been associated with a wide range of 
factors. One that has most consistently been linked to a high 
risk of ARC is younger age [30,36].
The use of renal replacement therapy (RRT) during β-lactam 
therapy also shows a strong and significant association with 
target attainment [19]. Not surprisingly, considering that β- 
lactam antibiotics are predominantly cleared via renal elimination. 
At the same time, these patients may be at risk for overexposure 
and toxicity due to the reduced elimination. Furthermore, in an 
obese patient cohort, RRT was identified as an independent risk 
factor for overdose and a protective factor for target attainment 
[26]. Predicting β-lactam concentrations during treatment with 
RRT (intermittent, prolonged or continuous) seem to be challen-
ging, as both volume of distribution and total drug clearance are 
affected, and both parameters may be significantly disturbed 
during critical illness. In addition, it is important to realize that 
the effect of RRT on target attainment may be unpredictably 
affected by for example the type of membrane, device settings, 
and intensity.
Higher doses and prolonged infusions are also clear predic-
tors for target attainment. Imani et al. found that prescribed 
daily antibiotic dose ≥ 1.5 times the product information (PI) 
recommendations were associated with better target attain-
ment [27]. Higher total daily dose is associated with the 
achievement of 100% ƒT >4× MIC for piperacillin [20]. 
Moreover, Carrie et al. showed that in critically ill patients with 
ARC, higher than licensed dosing regimens of β-lactam antibio-
tics may be safe and effective in reducing the rate of therapeu-
tic failure [37]. The total daily dose is not associated with 
achievement of 100% ƒT >MIC, because there was not a wide 
range of doses used in the studies, or alternatively, because the 
dose adjustments that were made for different levels of renal 
function prevented this being significant. However, in ARC 
patients, higher dosing than the licensed dosing regimens of β- 
lactam antibiotics may be safe and effective in reducing the 
rate of therapeutic failure [37]. Furthermore, the use of pro-
longed (extended or continuous) infusion is significantly asso-
ciated with the achievement target attainment [20,24]. In 
dosing simulations studies, extended or continuous infusion 
has also been demonstrated to increase the changes of target 
attainment [38–41].
Obesity has previously been proposed to be a risk factor for 
altered β-lactam concentrations in both non-critically ill and 
critically ill patients [42–45]. High body mass index (BMI) was 
a significant risk factor for target non-attainment [19]. With the 
increased prevalence of obesity in Western societies and no 
dosing guidelines available for critically ill obese patients, 
ensuring adequate β-lactam therapeutic concentrations is 
considered to be a serious challenge for clinicians.
Figure 2. Demographic and clinical factors associated with β-lactam target attainment. The thickness of the arrow is a representation of the associated evidence. 
The up arrows indicate that the probability of target attainment increases, the down arrows indicate that the probability of target attainment decreases.
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Finally, there are several other significant but less promi-
nent clinical predictors for target attainment. Target non- 
attainment is more frequently observed in patients with 
lower sequential organ failure assessment (SOFA) scores [27]. 
However, the presence of severe illness and especially the SIRS 
response, has also been shown to impact the volume of dis-
tribution for some antibiotics [46,47], making increased dosing 
and close monitoring necessary. Furthermore, positive micro-
biology cultures seem to be associated with target attainment 
[27]. Lastly, positive correlation was found between target 
attainment and high serum concentrations of bilirubin and 
urea [19,28].
3.4. Antimicrobial dosing strategies
For β-lactam antibiotics, an increase in %ƒT > MIC can be 
achieved particularly by increasing the number of daily doses 
or by providing extended or continuous infusion. Furthermore, 
dosing individualization based on population PK models and 
patient factors known to influence antimicrobial PK increases 
the probability of achieving therapeutic drug exposure while 
at the same time avoiding toxic concentrations. However, 
optimizing antimicrobial therapy still represents a complex 
challenge given the wide and unpredictable variability of 
antibiotic concentrations in critically ill patients. Indeed, the 
complexity and dynamic nature of critically ill patients make 
associations of clinical variables and the considered risk of 
target non-attainment difficult to apply without supporting 
tools. To enable the practical application of significant rela-
tionships between risk factors and β-lactam exposure, and 
consequently target attainment, risk assessment tools could 
provide guidance. Ehmann et al. developed an easy-to-use 
tool, MeroRisk Calculator, for the risk assessment of target 
non-attainment based on the renal function [48].
3.4.1. Workflow for dose individualization
Refined dosing strategies for antimicrobials are necessary to 
enhance the probability of achieving drug concentrations that 
increase the likelihood of clinical success in critically ill patients 
[49]. A workflow involving several steps is proposed to achieve 
optimal dosing in these patients (Figure 3). Firstly, antibiotic 
selection must be based on both relevant patient and patho-
gen factors. Subsequently, the selection of the correct dosing 
regimen takes place using tools such as guideline and dosing 
nomograms. In addition, dose individualization in critically ill 
patients based dose simulations and patient factors increases 
the probability of achieving therapeutic drug exposures, while 
at the same time avoiding toxic concentrations. Pending the 
result TDM, a higher daily dose of β-lactam antibiotics at 
the onset of treatment should be considered, especially in 
the most critically ill patients and in those with preserved 
renal function. Particularly in the case of patients with ARC, 
evidence is building up regarding the clinical impact of ARC 
and the potential need for increased doses in critically ill 
Figure 3. General steps to obtain antibiotic dose optimization (Modified form [54]).
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patients [50–52]. Finally, appropriate PK models coupled to PD 
targets can be used to improve dosing regimens based on 
adaptive feedback through TDM.
AUC/MIC: the ratio of the area under the concentration– 
time curve to MIC; Cmax/MIC: the ratio of maximum drug 
concentration to MIC; MIC: minimum inhibitory concentration; 
PK/PD: pharmacokinetic/pharmacodynamic; T> MIC: the dura-
tion of time that the drug concentration remains above the 
MIC during a dosing interval; TDM: Therapeutic drug 
monitoring.
3.4.2. Pharmacodynamic targets and outcome
The optimal pharmacodynamic target (PDT) is still not clearly 
defined for β-lactam antibiotics. The used PDTs in the included 
studies vary between 50% and 100% ƒT >MIC and 50–100% ƒT 
>4xMIC. However, 100% ƒT > MIC target attainment is 
reported in only 40% to 60% of critically ill patients treated 
with β-lactam antibiotics [5,19,53].
To maximize the probability of clinical efficacy in critically ill 
patients, unbound plasma concentration from one up to four 
times the MIC for 100% of the dosing interval (100% ƒT > 
1–4× MIC) is recommended [54–59], although the correlation 
with improved clinical outcomes is not well established. 
Further increasing the exposure does not appear to increase 
the rate and extent of bacterial killing or positive clinical out-
come [25,60].
For continuous infusions, a random concentration of at 
least 4xMIC is suggested. Toxicity of β-lactam antibiotics is 
rare, but can be serious. Neurotoxicity, especially convul-
sions, hallucinations, myoclonus and confusion, is described 
due to high concentrations of β-lactam antibiotics [61–65]. 
To avoid potentially toxic effects, dose reduction is arbitrarily 
recommended when the unbound trough levels exceeds 8– 
10xMIC [9,66,67].
There are two types of interventions commonly used to 
optimize beta-lactam exposure, which are modifying beta- 
lactam administration by increasing the duration of the infu-
sion and/or TDM and adjusting the dose based on serum 
levels. However, the clinical impact on patient’s prognosis 
using this strategy in critically ill patients is not yet fully 
demonstrated. The results from a multicenter randomized 
controlled trial investigating the effect of TDM of beta- 
lactams on clinical outcomes in critically ill patients are 
expected [68].
3.4.3. Prolonged infusion of β-lactams
Extended and continuous infusion of β-lactams is associated 
with better target attainment and cure rates in critically ill 
patients [69]. Recent meta-analyses have shown an association 
between extended infusion of β-lactams and lower mortality 
rates in critically ill patients with severe sepsis [70,71]. 
Especially for piperacillin-tazobactam and meropenem, 
extended or continuous infusion is strongly recommended 
based on high-quality evidence [71]. Prolonged infusion of β- 
lactams can facilitate in dose optimization in the critically ill 
patient are at risk for target non-attainment.
4. Conclusion
We provide an overview of evidence on factors associated β- 
lactam exposure in critically ill patients. Early identification of 
patients at risk when initiating empirical antibiotic therapy 
based on demographic and clinical risk factors 
has considerable clinical value. Based on the findings of this 
study, male gender, younger age, and augmented renal clear-
ance are the most significant predictors for target non- 
attainment of β-lactam antibiotics. Furthermore, these factors 
could be considered when developing algorithms to help 
optimize antibiotics therapy.
5. Expert opinion
Patients admitted to the ICU represent a highly heterogeneous 
population ranging from young trauma patients to postsurgical 
patients and elderly medical patients. This heterogeneity is well 
known to result in high variability in PK parameters. Β-lactam 
are hydrophilic antimicrobials, which experience increased 
volume of distribution, generally require a loading dose in 
patients with sepsis regardless of renal function. One should 
remind that patient’s clinical condition may change rapidly 
during the ICU stay, toward either improvement or degradation, 
which may subsequently lead to altered PK parameters.
Identifying at-risk patients when initiating therapy is a first 
step in dose optimization. However, since PK parameters vary 
considerably in ICU patients during therapy, exposure should 
be monitored in this population. TDM combined with popula-
tion PK models and dosing simulation can be used to interpret 
the complex and changing PK parameters in critically ill 
patients to improve target attainment. Yet, TDM of β-lactam 
antibiotics is not structurally performed due to the wide ther-
apeutic window of these agents and the lack of concrete dose 
recommendations in relation to the measured drug levels. 
However, in recent years, the increasing resistance to β- 
lactam antibiotics and the association with low levels has 
increased the relevance of TDM with β-lactam antibiotics. β- 
lactam TDM is recommended after the onset of treatment, 
after any change in dosage, and in the event of a significant 
change in the patient’s clinical condition [9,72].
In the present review some suggestions and solutions are 
offered based on the current knowledge. For the strong pre-
dictors regarding target attainment, we advise their integra-
tion into practice. Currently, the expansion of screening 
software provides an important tool to assist clinicians in the 
detection and management of under or overdosing. Yet, for 
demographic and clinical factors, and even for strongly sub-
stantiated associations, translation into clinical recommenda-
tions is still lacking in clinical practice. Our findings imply the 
need for dosing intensification in patients identified to be at 
risk of target non-attainment. Understanding which factors are 
responsible for the variability of β-lactam exposure would help 
predict and adjust the dosing strategy in each patient during 
the ICU stay and therefore optimize antimicrobial effective-
ness. Thus, it appears possible to adjust the β-lactam dosage 
by taking into account demographic and clinical factors, until 
the plasma concentration data are available.
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